HHS OIG To Investigate Drug Shortages, Rebates, Other Pharma Issues In 2013
A number of topical issues will be investigated by the HHS Office of Inspector General, according to its work plan for fiscal year 2013. Pharma industry issues are concentrated in the Medicare and Medicaid space.
You may also be interested in...
OIG is examining how Medicare could benefit if it shared in the drug discounts available through the 340B program, the potential impact of changes to Part B ASP reporting and other Medicare and Medicaid drug-related topics during this and the coming fiscal year.
Sen. Wyden questions Xeljanz pricing at Senate hearing and Sen. Nelson wants new OIG review of Medicaid versus Medicare drug rebates. GAO compares VA, DoD drug purchasing in report.
A review of Part D plan design trends among the leading sponsors shows that Humana has switched to five-tier formularies, UnitedHealth is using a preferred pharmacy network and CVS Caremark is sponsoring plans that include community-based independents in its preferred network.